论文部分内容阅读
目的:分析研究慢性乙型肝炎采用抗病毒治疗的临床治疗效果。方法:抽取近年来在我院收治的患有慢性乙型肝炎的病人120例,采用随机抽取模式,随机分为实验组和对照组,每组各60例。对照组对病人采用常规临床治疗模式,实验组对病人实施抗病毒药物当中的安福隆(重组人干扰素α2b注射液)以及拉米夫定治疗,对两组病人在经过临床治疗以后的治疗效果进行对比分析。结果:通过临床治疗以后,实验组肝脏功能复恢复正常率显著优于对照组,两组间差异具有统计学意义(P<0.05);实验组HBV DNA转阴率和HBeAg转阴率差异具有统计学意义(P<0.05),并随着治疗时间延长,经过半年跟踪随访的时候,实验组HBeAg转阴率更加优于对照组,两组间差异具有统计学意义(P<0.05);并随着时间的延长其差异更加明显。结论:对慢性乙型肝炎采用抗病毒治疗,可以取得明显的临床治疗效果,使机体免疫功能和抵抗病毒能力明显提高,不良反应少,具有安全有效性,使病人的健康生活质量得到保障,具有临床推广价值。
Objective: To analyze the clinical effect of antiviral therapy on chronic hepatitis B. Methods: A total of 120 patients with chronic hepatitis B admitted to our hospital in recent years were randomly divided into experimental group and control group with 60 cases in each group. The patients in the control group were treated with routine clinical therapy. The patients in the experimental group were given An Fulong (recombinant human interferon α2b injection) and lamivudine in the antiviral drugs. The therapeutic effect of the two groups of patients after clinical treatment For comparative analysis. Results: After clinical treatment, the recovery rate of liver function in experimental group was significantly better than that in control group, with significant difference between the two groups (P <0.05). There was statistical difference between negative rate of HBV DNA and negative rate of HBeAg in experimental group (P <0.05). With the prolongation of treatment time, HBeAg negative rate in the experimental group was better than that in the control group after six months’ follow-up. The difference between the two groups was statistically significant (P <0.05) The longer the difference between the more obvious. Conclusion: Antiviral treatment of chronic hepatitis B can achieve significant clinical treatment effect, significantly improve immune function and virus resistance, fewer adverse reactions, safety and effectiveness, and ensure the quality of life of patients with Clinical promotion value.